XNAS 14 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2026 | 15,940 | 82,816 (0%) | 0% | 0 | - | |
| Mr. John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.51 per share. | 28 Sep 2026 | 5,562 | 77,254 (0%) | 0% | 72.5 | 403,301 | - |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Sep 2026 | 15,940 | 62,443 (0%) | 0% | 0 | - | |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.55 per share. | 22 Sep 2026 | 5,559 | 56,884 (0%) | 0% | 72.5 | 403,305 | - |
| Mr. James T. Hippel | CFO | 17 Aug 2026 | 22,438 | 22,438 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 17 Aug 2026 | 36,459 | 36,459 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 17 Aug 2026 | 93,582 | 93,582 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 17 Aug 2026 | 57,590 | 57,590 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 17 Aug 2026 | 23,985 | 23,985 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 17 Aug 2026 | 14,762 | 14,762 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 17 Aug 2026 | 18,432 | 18,432 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 17 Aug 2026 | 11,344 | 11,344 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | 17 Aug 2026 | 1,381 | 1,381 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2026 | 4,350 | 11,703 (0%) | 0% | 0 | Common Stock | |
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2026 | 2,332 | 4,664 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2026 | 1,669 | 1,669 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2026 | 4,502 | 0 | - | - | Performance Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2026 | 300 | 4,502 | - | - | Performance Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2026 | 12,117 | 807 | - | - | Performance Stock Option (Right to Buy) | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2026 | 49 | 0 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.40 per share. | 15 Aug 2026 | 1,343 | 10,360 (0%) | 0% | 72.4 | 97,233 | Common Stock |
| Dr. Amy Herr, PhD | Director | 15 Aug 2026 | 311 | 621 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | 15 Aug 2026 | 160 | 160 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | 15 Aug 2026 | 118 | 0 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.40 per share. | 15 Aug 2026 | 213 | 576 (0%) | 0% | 72.4 | 15,421 | Common Stock |
| Dr. Amy Herr, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2026 | 589 | 789 (0%) | 0% | 0 | Common Stock | |
| Mr. James T. Hippel | CFO | 15 Aug 2026 | 4,903 | 9,807 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2026 | 4,010 | 4,011 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2026 | 34,982 | 2,332 | - | - | Performance Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 15 Aug 2026 | 12,999 | 0 | - | - | Performance Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2026 | 866 | 12,999 | - | - | Performance Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.40 per share. | 15 Aug 2026 | 4,310 | 170,183 (0%) | 0% | 72.4 | 312,044 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2026 | 9,779 | 174,493 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.40 per share. | 15 Aug 2026 | 10,821 | 82,762 (0%) | 0% | 72.4 | 783,440 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2026 | 21,470 | 93,583 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 11,785 | 23,569 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 8,543 | 8,544 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 24,324 | 1,621 | - | - | Performance Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 8,835 | 0 | - | - | Performance Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 588 | 8,835 | - | - | Performance Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 22,389 | 1,492 | - | - | Performance Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 8,319 | 0 | - | - | Performance Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2026 | 554 | 8,319 | - | - | Performance Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.40 per share. | 15 Aug 2026 | 1,976 | 24,943 (0%) | 0% | 72.4 | 143,062 | Common Stock |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2026 | 3,226 | 6,452 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2026 | 2,623 | 2,623 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2026 | 22,898 | 1,526 | - | - | Performance Stock Options (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2026 | 8,507 | 0 | - | - | Performance Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2026 | 567 | 8,507 | - | - | Performance Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2026 | 6,416 | 26,919 (0%) | 0% | 0 | Common Stock | |
| Mr. James T. Hippel | CFO | 29 Jul 2026 | 62,068 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.03 per share. | 29 Jul 2026 | 51,024 | 164,714 (0%) | 0% | 72.0 | 3,675,259 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 29 Jul 2026 | 62,068 | 215,738 (0%) | 0% | 47.6 | 2,954,437 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 28 Jul 2026 | 35,000 | 100,799 (0%) | 0% | 47.6 | 1,666,000 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 28 Jul 2026 | 35,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.07 per share. | 28 Jul 2026 | 28,686 | 72,113 (0%) | 0% | 72.1 | 2,067,400 | Common Stock |
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 23 Jul 2026 | 448 | 7,697 (0%) | 0% | 47.6 | 21,325 | Common Stock |
| Mr. Shane Bohnen | SVP - General Counsel | 23 Jul 2026 | 448 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.77 per share. | 23 Jul 2026 | 344 | 7,353 (0%) | 0% | 71.8 | 24,689 | Common Stock |
| Dr. Amy Herr, PhD | Director | 08 May 2026 | 6,636 | 0 | - | - | Stock Option (Right to Buy) | ||
| Dr. Amy Herr, PhD | Director | Sale of securities on an exchange or to another person at price $ 48.28 per share. | 08 May 2026 | 6,636 | 200 (0%) | 0% | 48.3 | 320,386 | Common Stock |
| Dr. Amy Herr, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 08 May 2026 | 6,636 | 6,836 (0%) | 0% | 47.6 | 315,874 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 05 May 2026 | 62,000 | 210,625 (0%) | 0% | 47.6 | 2,951,200 | Common Stock |
| Mr. James T. Hippel | CFO | 05 May 2026 | 62,000 | 62,068 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.68 per share. | 05 May 2026 | 56,955 | 153,670 (0%) | 0% | 56.7 | 3,228,209 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 05 May 2026 | 26,692 | 35,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.68 per share. | 05 May 2026 | 23,951 | 65,799 (0%) | 0% | 56.7 | 1,357,543 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 05 May 2026 | 26,692 | 89,750 (0%) | 0% | 47.6 | 1,270,539 | Common Stock |
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 05 May 2026 | 8,400 | 14,304 (0%) | 0% | 47.6 | 399,840 | Common Stock |
| Mr. Shane Bohnen | SVP - General Counsel | 05 May 2026 | 8,400 | 448 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.68 per share. | 05 May 2026 | 7,055 | 7,249 (0%) | 0% | 56.7 | 399,877 | Common Stock |
| Mr. James T. Hippel | CFO | 22 Apr 2026 | 62,000 | 124,068 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.58 per share. | 22 Apr 2026 | 56,097 | 148,625 (0%) | 0% | 58.6 | 3,286,162 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 62,000 | 204,722 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 11,344 | 64,421 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 22 Apr 2026 | 11,344 | 61,692 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.58 per share. | 22 Apr 2026 | 1,363 | 63,058 (0%) | 0% | 58.6 | 79,845 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 11,344 | 64,421 (0%) | 0% | 0 | - | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.58 per share. | 22 Apr 2026 | 1,363 | 63,058 (0%) | 0% | 58.6 | 79,845 | - |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 62,000 | 204,722 (0%) | 0% | 0 | - | |
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.58 per share. | 22 Apr 2026 | 56,097 | 148,625 (0%) | 0% | 58.6 | 3,286,162 | - |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 14 Apr 2026 | 36,500 | 73,036 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.66 per share. | 14 Apr 2026 | 32,088 | 53,077 (0%) | 0% | 58.7 | 1,882,282 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 36,500 | 85,165 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 36,500 | 85,165 (0%) | 0% | 0 | - | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.66 per share. | 14 Apr 2026 | 32,088 | 53,077 (0%) | 0% | 58.7 | 1,882,282 | - |
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2026 | 2,259 | 6,644 (0%) | 0% | 0 | Common Stock | |
| Mr. Shane Bohnen | SVP - General Counsel | 03 Apr 2026 | 2,259 | 0 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.13 per share. | 03 Apr 2026 | 740 | 5,904 (0%) | 0% | 53.1 | 39,316 | Common Stock |
| Dr. Amy Herr, PhD | Director | Sale of securities on an exchange or to another person at price $ 59.10 per share. | 17 Feb 2026 | 1,976 | 200 (0%) | 0% | 59.1 | 116,791 | Common Stock |
| Dr. Amy Herr, PhD | Director | 03 Feb 2026 | 38 | 77 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 38 | 2,192 (0%) | 0% | 0 | Common Stock | |
| Dr. Amy Herr, PhD | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.62 per share. | 03 Feb 2026 | 16 | 2,176 (0%) | 0% | 64.6 | 1,034 | Common Stock |
| Dr. Matthew McManus | President - Diag & Spatial Bio | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 4,621 | 9,356 (0%) | 0% | 0 | Common Stock | |
| Dr. Matthew McManus | President - Diag & Spatial Bio | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.09 per share. | 01 Feb 2026 | 1,665 | 7,691 (0%) | 0% | 64.1 | 106,710 | Common Stock |
| Dr. Matthew McManus | President - Diag & Spatial Bio | 01 Feb 2026 | 4,621 | 4,620 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 13,159 | 143,042 (0%) | 0% | 0 | Common Stock | |
| Mr. James T. Hippel | CFO | 03 Nov 2025 | 11,545 | 23,089 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 03 Nov 2025 | 13,159 | 0 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.57 per share. | 03 Nov 2025 | 11,865 | 142,722 (0%) | 0% | 62.6 | 742,393 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 11,545 | 154,587 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.57 per share. | 03 Nov 2025 | 2,303 | 48,665 (0%) | 0% | 62.6 | 144,099 | Common Stock |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 03 Nov 2025 | 9,911 | 0 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.57 per share. | 03 Nov 2025 | 4,520 | 20,503 (0%) | 0% | 62.6 | 282,816 | Common Stock |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 9,911 | 25,023 (0%) | 0% | 0 | Common Stock | |
| Mr. John L. Higgins | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 66,876 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph D. Keegan, PhD | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Options (Right to Buy) | ||
| Dr. Joseph D. Keegan, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 15,411 (0%) | 0% | 0 | Common Stock | |
| Mr. Robert V. Baumgartner, C.P.A. | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Options (Right to Buy) | ||
| Mr. Robert V. Baumgartner, C.P.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 46,503 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 8,775 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie L. Bushman | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Options (Right to Buy) | ||
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Options (Right to Buy) | ||
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 10,987 (0%) | 0% | 0 | Common Stock | |
| Dr. Alpna Seth, PhD | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Options (Right to Buy) | ||
| Dr. Alpna Seth, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 15,411 (0%) | 0% | 0 | Common Stock | |
| Dr. Judith Klimovsky, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 3,782 (0%) | 0% | 0 | Common Stock | |
| Dr. Judith Klimovsky, M.D. | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Option (Right to Buy) | ||
| Dr. Amy Herr, PhD | Director | 30 Oct 2025 | 3,777 | 3,777 | - | - | Stock Option (Right to Buy) | ||
| Dr. Amy Herr, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2025 | 1,640 | 2,680 (0%) | 0% | 0 | Common Stock | |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.84 per share. | 25 Aug 2025 | 17,040 | 61,903 (0%) | 0% | 21.8 | 372,154 | Common Stock |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Sale of securities on an exchange or to another person at price $ 56.21 per share. | 25 Aug 2025 | 17,040 | 44,863 (0%) | 0% | 56.2 | 957,818 | Common Stock |
| Mr. Robert V. Baumgartner, C.P.A. | Director | 25 Aug 2025 | 17,040 | 0 | - | - | Stock Options (Right to Buy) | ||
| Dr. Roeland Nusse,PhD | Director | 25 Aug 2025 | 17,040 | 0 | - | - | Stock Options (Right to Buy) | ||
| Dr. Roeland Nusse,PhD | Director | Sale of securities on an exchange or to another person at price $ 56.36 per share. | 25 Aug 2025 | 17,040 | 44,559 (0%) | 0% | 56.4 | 960,388 | Common Stock |
| Dr. Roeland Nusse,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.84 per share. | 25 Aug 2025 | 17,040 | 61,599 (0%) | 0% | 21.8 | 372,154 | Common Stock |
| Mr. James T. Hippel | CFO | 15 Aug 2025 | 37,632 | 37,632 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 4,010 | 131,809 (0%) | 0% | 0 | Common Stock | |
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.60 per share. | 15 Aug 2025 | 1,926 | 129,883 (0%) | 0% | 53.6 | 103,234 | Common Stock |
| Mr. James T. Hippel | CFO | 15 Aug 2025 | 4,010 | 8,021 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2025 | 29,420 | 29,420 | - | - | Performance Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2025 | 14,710 | 14,710 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2025 | 8,543 | 17,087 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.60 per share. | 15 Aug 2025 | 4,305 | 50,968 (0%) | 0% | 53.6 | 230,748 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 8,543 | 55,273 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2025 | 90,441 | 90,441 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2025 | 35,354 | 35,354 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2025 | 70,708 | 70,708 | - | - | Performance Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2025 | 24,758 | 24,758 | - | - | Stock Options (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.60 per share. | 15 Aug 2025 | 803 | 15,112 (0%) | 0% | 53.6 | 43,041 | Common Stock |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 2,623 | 15,915 (0%) | 0% | 0 | Common Stock | |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2025 | 9,678 | 9,678 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2025 | 19,355 | 19,355 | - | - | Performance Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2025 | 2,623 | 5,246 | - | - | Restricted Stock Units | ||
| Dr. Matthew McManus | President - Diag & Spatial Bio | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.60 per share. | 15 Aug 2025 | 880 | 4,735 (0%) | 0% | 53.6 | 47,168 | Common Stock |
| Dr. Matthew McManus | President - Diag & Spatial Bio | 15 Aug 2025 | 24,614 | 24,614 | - | - | Stock Option (Right to Buy) | ||
| Dr. Matthew McManus | President - Diag & Spatial Bio | 15 Aug 2025 | 9,622 | 9,622 | - | - | Restricted Stock Units | ||
| Dr. Matthew McManus | President - Diag & Spatial Bio | 15 Aug 2025 | 19,243 | 19,243 | - | - | Performance Restricted Stock Units | ||
| Dr. Matthew McManus | President - Diag & Spatial Bio | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 2,637 | 5,615 (0%) | 0% | 0 | Common Stock | |
| Dr. Matthew McManus | President - Diag & Spatial Bio | 15 Aug 2025 | 2,637 | 5,275 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2025 | 17,897 | 17,897 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2025 | 6,996 | 6,996 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2025 | 13,992 | 13,992 | - | - | Performance Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2025 | 1,668 | 3,338 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2025 | 50 | 49 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.60 per share. | 15 Aug 2025 | 527 | 4,385 (0%) | 0% | 53.6 | 28,247 | Common Stock |
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 1,718 | 4,912 (0%) | 0% | 0 | Common Stock | |
| Dr. Amy Herr, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 279 | 2,255 (0%) | 0% | 0 | Common Stock | |
| Dr. Amy Herr, PhD | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.60 per share. | 15 Aug 2025 | 101 | 2,154 (0%) | 0% | 53.6 | 5,414 | Common Stock |
| Dr. Amy Herr, PhD | Director | 15 Aug 2025 | 119 | 118 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | 15 Aug 2025 | 160 | 320 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | 15 Aug 2025 | 932 | 932 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | 15 Aug 2025 | 2,735 | 2,735 | - | - | Stock Option (Right to Buy) | ||
| Mr. John L. Higgins | Director | 07 Aug 2025 | 5,040 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.84 per share. | 07 Aug 2025 | 5,040 | 65,236 (0%) | 0% | 21.8 | 110,074 | Common Stock |
| Mr. James T. Hippel | CFO | 29 Jul 2025 | 168,620 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.55 per share. | 29 Jul 2025 | 147,431 | 127,799 (0%) | 0% | 58.5 | 8,632,085 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.33 per share. | 29 Jul 2025 | 168,620 | 275,230 (0%) | 0% | 44.3 | 7,474,925 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 22 Jul 2025 | 48,176 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.12 per share. | 22 Jul 2025 | 43,649 | 46,730 (0%) | 0% | 53.1 | 2,318,635 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.33 per share. | 22 Jul 2025 | 48,176 | 90,379 (0%) | 0% | 44.3 | 2,135,642 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.33 per share. | 15 Jul 2025 | 36,132 | 75,136 (0%) | 0% | 44.3 | 1,601,732 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Jul 2025 | 36,132 | 48,176 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.42 per share. | 15 Jul 2025 | 32,933 | 42,203 (0%) | 0% | 51.4 | 1,693,415 | Common Stock |
| Dr. Amy Herr, PhD | Director | 09 Jun 2025 | 1,280 | 0 | - | - | Stock Option (Right to Buy) | ||
| Dr. Amy Herr, PhD | Director | Sale of securities on an exchange or to another person at price $ 49.77 per share. | 09 Jun 2025 | 1,280 | 1,976 (0%) | 0% | 49.8 | 63,705 | Common Stock |
| Dr. Amy Herr, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.33 per share. | 09 Jun 2025 | 1,280 | 3,256 (0%) | 0% | 44.3 | 56,742 | Common Stock |
| Mr. John L. Higgins | Director | 01 May 2025 | 12,000 | 5,040 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.84 per share. | 01 May 2025 | 12,000 | 60,196 (0%) | 0% | 21.8 | 262,080 | Common Stock |
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2025 | 2,260 | 3,941 (0%) | 0% | 0 | Common Stock | |
| Mr. Shane Bohnen | SVP - General Counsel | 03 Apr 2025 | 2,260 | 2,259 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.86 per share. | 03 Apr 2025 | 747 | 3,194 (0%) | 0% | 54.9 | 40,980 | Common Stock |
| Dr. Amy Herr, PhD | Director | 14 Feb 2025 | 1,976 | 1,280 | - | - | Stock Option (Right to Buy) | ||
| Dr. Amy Herr, PhD | Director | Sale of securities on an exchange or to another person at price $ 65.96 per share. | 14 Feb 2025 | 1,860 | 1,976 (0%) | 0% | 66.0 | 122,691 | Common Stock |
| Dr. Amy Herr, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.33 per share. | 14 Feb 2025 | 1,976 | 3,836 (0%) | 0% | 44.3 | 87,596 | Common Stock |
| Dr. Amy Herr, PhD | Director | 03 Feb 2025 | 115 | 115 | - | - | Restricted Stock Units | ||
| Dr. Amy Herr, PhD | Director | 03 Feb 2025 | 344 | 344 | - | - | Stock Option (Right to Buy) | ||
| Dr. Amy Herr, PhD | Director | 03 Feb 2025 | 2,415 | 2,415 | - | - | Stock Option (Right to Buy) | ||
| Dr. Amy Herr, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 1,040 | 1,040 (0%) | 0% | 0 | Common Stock | |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 3,320 | 14,401 (0%) | 0% | 0 | Common Stock | |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 01 Feb 2025 | 3,320 | 0 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.55 per share. | 01 Feb 2025 | 1,109 | 13,292 (0%) | 0% | 73.6 | 81,567 | Common Stock |
| Dr. Matthew McManus | President - DGS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 4,620 | 4,620 (0%) | 0% | 0 | Common Stock | |
| Dr. Matthew McManus | President - DGS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.55 per share. | 01 Feb 2025 | 1,642 | 2,978 (0%) | 0% | 73.5 | 120,769 | Common Stock |
| Dr. Matthew McManus | President - DGS | 01 Feb 2025 | 4,620 | 9,241 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.70 per share. | 27 Jan 2025 | 13,392 | 52,396 (0%) | 0% | 37.7 | 504,878 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.19 per share. | 27 Jan 2025 | 11,731 | 40,665 (0%) | 0% | 77.2 | 905,533 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.95 per share. | 27 Jan 2025 | 1,661 | 39,004 (0%) | 0% | 78.0 | 129,480 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 27 Jan 2025 | 13,392 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 01 Nov 2024 | 13,159 | 13,159 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 6,475 | 106,610 (0%) | 0% | 75.3 | 487,632 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 13,159 | 113,085 (0%) | 0% | 0 | Common Stock | |
| Mr. James T. Hippel | CFO | 01 Nov 2024 | 34,634 | 34,634 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 2,430 | 39,004 (0%) | 0% | 75.3 | 183,003 | Common Stock |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 01 Nov 2024 | 9,912 | 9,911 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 3,270 | 11,081 (0%) | 0% | 75.3 | 246,264 | Common Stock |
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,912 | 14,351 (0%) | 0% | 0 | Common Stock | |
| Mr. John L. Higgins | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 48,196 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph D. Keegan, PhD | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | ||
| Dr. Joseph D. Keegan, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 13,771 (0%) | 0% | 0 | Common Stock | |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 44,863 (0%) | 0% | 0 | Common Stock | |
| Mr. Robert V. Baumgartner, C.P.A. | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | ||
| Dr. Roeland Nusse,PhD | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | ||
| Dr. Roeland Nusse,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 44,559 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie L. Bushman | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | ||
| Ms. Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 7,135 (0%) | 0% | 0 | Common Stock | |
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | ||
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 9,347 (0%) | 0% | 0 | Common Stock | |
| Dr. Alpna Seth, PhD | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | ||
| Dr. Alpna Seth, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 13,771 (0%) | 0% | 0 | Common Stock | |
| Dr. Judith Klimovsky, M.D. | Director | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Option (Right to Buy) | ||
| Dr. Judith Klimovsky, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 2,142 (0%) | 0% | 0 | Common Stock | |
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 12 Sep 2024 | 6,000 | 48,608 (0%) | 0% | 23.0 | 137,700 | Common Stock |
| Mr. John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.20 per share. | 12 Sep 2024 | 1,874 | 46,734 (0%) | 0% | 73.2 | 137,177 | Common Stock |
| Mr. John L. Higgins | Director | 12 Sep 2024 | 6,000 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.97 per share. | 29 Aug 2024 | 1,492 | 41,434 (0%) | 0% | 67.0 | 99,919 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 29 Aug 2024 | 1,492 | 115,724 | - | - | Stock Option (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 15 Aug 2024 | 32,417 | 32,417 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 15 Aug 2024 | 12,031 | 12,031 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2024 | 24,062 | 24,062 | - | - | Performance Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2024 | 69,061 | 69,061 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2024 | 25,630 | 25,630 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | 15 Aug 2024 | 51,261 | 51,261 | - | - | Performance Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2024 | 21,204 | 21,204 | - | - | Stock Options (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2024 | 7,869 | 7,869 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2024 | 15,738 | 15,738 | - | - | Performance Restricted Stock Units | ||
| Dr. Matthew McManus | President - DGS | 15 Aug 2024 | 21,320 | 21,320 | - | - | Stock Option (Right to Buy) | ||
| Dr. Matthew McManus | President - DGS | 15 Aug 2024 | 7,912 | 7,912 | - | - | Restricted Stock Units | ||
| Dr. Matthew McManus | President - DGS | 15 Aug 2024 | 15,818 | 15,818 | - | - | Performance Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 49 | 1,696 (0%) | 0% | 0 | Common Stock | |
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2024 | 13,488 | 13,488 | - | - | Stock Option (Right to Buy) | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2024 | 5,006 | 5,006 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2024 | 10,012 | 10,012 | - | - | Performance Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2024 | 49 | 99 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.93 per share. | 15 Aug 2024 | 15 | 1,681 (0%) | 0% | 74.9 | 1,124 | Common Stock |
| Dr. Matthew McManus | President - DGS | 15 Aug 2024 | 15,825 | 15,825 | - | - | Performance Restricted Stock Units | ||
| Mr. Robert V. Baumgartner, C.P.A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 08 Aug 2024 | 16,000 | 59,401 (0%) | 0% | 23.0 | 367,200 | Common Stock |
| Mr. Robert V. Baumgartner, C.P.A. | Director | 08 Aug 2024 | 16,000 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. Robert V. Baumgartner, C.P.A. | Director | Sale of securities on an exchange or to another person at price $ 72.10 per share. | 08 Aug 2024 | 16,000 | 43,401 (0%) | 0% | 72.1 | 1,153,664 | Common Stock |
| Mr. James T. Hippel | CFO | 02 Aug 2024 | 53,000 | 53,867 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.35 per share. | 02 Aug 2024 | 36,076 | 99,926 (0%) | 0% | 82.4 | 2,970,859 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 02 Aug 2024 | 53,000 | 136,002 (0%) | 0% | 31.3 | 1,656,780 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.70 per share. | 31 Jul 2024 | 14,000 | 49,421 (0%) | 0% | 37.7 | 527,800 | Common Stock |
| Mr. Kim Kelderman | Director, Chief Executive Officer | 31 Jul 2024 | 14,000 | 13,392 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.97 per share. | 31 Jul 2024 | 9,479 | 39,942 (0%) | 0% | 82.0 | 776,994 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 23 Jul 2024 | 35,000 | 107,284 (0%) | 0% | 31.3 | 1,094,100 | Common Stock |
| Mr. James T. Hippel | CFO | 23 Jul 2024 | 35,000 | 106,867 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.77 per share. | 23 Jul 2024 | 24,282 | 83,002 (0%) | 0% | 77.8 | 1,888,411 | Common Stock |
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 08 Jul 2024 | 6,000 | 42,608 (0%) | 0% | 23.0 | 137,700 | Common Stock |
| Mr. John L. Higgins | Director | 08 Jul 2024 | 6,000 | 6,000 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | 14 May 2024 | 4,000 | 12,000 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 83.84 per share. | 14 May 2024 | 4,000 | 36,608 (0%) | 0% | 83.8 | 335,377 | Common Stock |
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 14 May 2024 | 4,000 | 40,608 (0%) | 0% | 23.0 | 91,800 | Common Stock |
| Dr. Judith Klimovsky, M.D. | Director | 01 May 2024 | 1,610 | 1,610 | - | - | Stock Option (Right to Buy) | ||
| Dr. Judith Klimovsky, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 680 | 680 (0%) | 0% | 0 | Common Stock | |
| Mr. Shane Bohnen | SVP - General Counsel | 03 Apr 2024 | 2,259 | 4,519 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.87 per share. | 03 Apr 2024 | 747 | 1,647 (0%) | 0% | 67.9 | 50,699 | Common Stock |
| Mr. Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 2,259 | 2,394 (0%) | 0% | - | Common Stock | |
| Dr. Roeland Nusse,PhD | Director | Sale of securities on an exchange or to another person at price $ 76.98 per share. | 07 Mar 2024 | 10,400 | 43,097 (0%) | 0% | 77.0 | 800,627 | Common Stock |
| Dr. Matthew McManus | President - DGS | 01 Feb 2024 | 2,888 | 2,888 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.54 per share. | 01 Feb 2024 | 1,111 | 7,759 (0%) | 0% | 68.5 | 76,148 | Common Stock |
| Dr. Matthew McManus | President - DGS | 01 Feb 2024 | 13,861 | 13,861 | - | - | Restricted Stock Units | ||
| Dr. Matthew McManus | President - DGS | 01 Feb 2024 | 7,951 | 7,951 | - | - | Stock Option (Right to Buy) | ||
| Dr. Matthew McManus | President - DGS | 01 Feb 2024 | 15,902 | 15,902 | - | - | Stock Option (Right to Buy) | ||
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.42 per share. | 19 Dec 2023 | 32,966 | 71,884 (0%) | 0% | 77.4 | 2,552,228 | Common Stock |
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 19 Dec 2023 | 47,289 | 104,850 (0%) | 0% | 31.3 | 1,478,254 | Common Stock |
| Mr. James T. Hippel | CFO | 19 Dec 2023 | 47,289 | 141,867 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Chief Operating Officer | 01 Nov 2023 | 9,423 | 9,423 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Chief Operating Officer | 01 Nov 2023 | 51,890 | 51,890 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Chief Operating Officer | 01 Nov 2023 | 25,945 | 25,945 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 14,196 | 35,421 (0%) | 0% | 0 | - | |
| Dr. Randolph C. Steer,M.D.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 24,201 (0%) | 0% | 0 | - | |
| Dr. Roeland Nusse,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 53,497 (0%) | 0% | 0 | - | |
| Dr. Alpna Seth, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 12,309 (0%) | 0% | 0 | - | |
| Ms. Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 5,673 (0%) | 0% | 0 | - | |
| Mr. John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 36,608 (0%) | 0% | 0 | - | |
| Dr. Joseph D. Keegan, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 12,309 (0%) | 0% | 0 | - | |
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 7,885 (0%) | 0% | 0 | - | |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2023 | 1,625 | 43,401 (0%) | 0% | 0 | - | |
| Dr. Roeland Nusse,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.85 per share. | 30 Aug 2023 | 16,000 | 44,811 (0%) | 0% | 21.9 | 349,600 | - |
| Dr. Roeland Nusse,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 30 Aug 2023 | 16,000 | 60,811 (0%) | 0% | 23.0 | 367,200 | - |
| Dr. Roeland Nusse,PhD | Director | Sale of securities on an exchange or to another person at price $ 80.32 per share. | 30 Aug 2023 | 8,939 | 51,872 (0%) | 0% | 80.3 | 717,959 | - |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 24 Aug 2023 | 2,100 | 21,225 (0%) | 0% | 47.6 | 99,960 | Common Stock |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 24 Aug 2023 | 2,100 | 109,536 | - | - | Stock Option (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2023 | 9,074 | 9,074 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 15 Aug 2023 | 8,873 | 8,873 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2023 | 12,924 | 12,924 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 15 Aug 2023 | 23,881 | 23,881 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 15 Aug 2023 | 37,314 | 37,314 | - | - | Stock Options (Right to Buy) | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2023 | 4,802 | 4,802 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2023 | 24,424 | 24,424 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 15 Aug 2023 | 13,865 | 13,865 | - | - | Restricted Stock Units | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 17,632 | 1,286,944 (3%) | 0% | 0 | Common Stock | |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.61 per share. | 15 Aug 2023 | 8,675 | 1,278,269 (3%) | 0% | 84.6 | 733,992 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 15 Aug 2023 | 59,095 | 59,095 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2023 | 12,798 | 12,798 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2023 | 34,442 | 34,442 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 15 Aug 2023 | 45,923 | 45,923 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 15 Aug 2023 | 29,391 | 29,391 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 15 Aug 2023 | 22,043 | 22,043 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 15 Aug 2023 | 8,191 | 8,191 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2023 | 30,059 | 30,059 | - | - | Stock Options (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2023 | 22,544 | 22,544 | - | - | Stock Options (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2023 | 8,377 | 8,377 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2023 | 148 | 148 | - | - | Restricted Stock Units | ||
| Mr. Shane Bohnen | SVP - General Counsel | 15 Aug 2023 | 16,302 | 16,302 | - | - | Stock Option (Right to Buy) | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Aug 2023 | 9,008 | 1,269,312 (3%) | 0% | 0 | Common Stock | |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 51,516 | 1,310,282 (3%) | 0% | 0 | Common Stock | |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 31,962 | 1,278,320 (3%) | 0% | 82.2 | 2,626,318 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 05 Aug 2023 | 51,516 | 0 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 12,876 | 63,896 (0%) | 0% | 0 | Common Stock | |
| Mr. James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 6,335 | 57,561 (0%) | 0% | 82.2 | 520,547 | Common Stock |
| Mr. James T. Hippel | CFO | 05 Aug 2023 | 12,876 | 0 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 05 Aug 2023 | 8,060 | 0 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 4,139 | 19,125 (0%) | 0% | 82.2 | 340,102 | Common Stock |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 8,060 | 23,264 (0%) | 0% | 0 | Common Stock | |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.36 per share. | 21 Jul 2023 | 80,000 | 1,258,766 (3%) | 0% | 88.4 | 7,069,024 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 30 Jun 2023 | 616,676 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.63 per share. | 30 Jun 2023 | 390,727 | 1,338,766 (3%) | 1% | 81.6 | 31,895,045 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.65 per share. | 30 Jun 2023 | 616,676 | 1,729,493 (4%) | 1% | 26.6 | 16,434,415 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.00 per share. | 07 Jun 2023 | 322 | 1,112,817 (2%) | 0% | 83 | 26,726 | Common Stock |
| Mr. John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.88 per share. | 28 Apr 2023 | 4,377 | 34,983 (0%) | 0% | 79.9 | 349,635 | Common Stock |
| Mr. John L. Higgins | Director | 28 Apr 2023 | 16,000 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.85 per share. | 28 Apr 2023 | 16,000 | 39,360 (0%) | 0% | 21.9 | 349,600 | Common Stock |
| Dr. Roeland Nusse,PhD | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Apr 2023 | 377 | 28,811 (0%) | 0% | 0 | Common Stock | |
| Mr. Shane Bohnen | SVP - General Counsel | 03 Apr 2023 | 3,928 | 3,928 | - | - | Stock Option (right to buy) | ||
| Mr. Shane Bohnen | SVP - General Counsel | 03 Apr 2023 | 6,778 | 6,778 | - | - | Restricted Stock Units | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.65 per share. | 04 Jan 2023 | 407,364 | 1,368,976 (3%) | 1% | 26.7 | 10,856,251 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.39 per share. | 04 Jan 2023 | 255,837 | 1,113,139 (2%) | 0% | 84.4 | 21,590,084 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 04 Jan 2023 | 407,364 | 616,676 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 5,840 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph D. Keegan, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 2,671 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph D. Keegan, PhD | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Dr. Randolph C. Steer,M.D.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 5,644 (0%) | 0% | 0 | Common Stock | |
| Dr. Randolph C. Steer,M.D.,PhD | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Mr. Robert V. Baumgartner, C.P.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 10,444 (0%) | 0% | 0 | Common Stock | |
| Mr. Robert V. Baumgartner, C.P.A. | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Dr. Roeland Nusse,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 7,297 (0%) | 0% | 0 | Common Stock | |
| Dr. Roeland Nusse,PhD | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Ms. Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 1,012 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie L. Bushman | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 1,565 (0%) | 0% | 0 | Common Stock | |
| Dr. Alpna Seth, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 2,671 (0%) | 0% | 0 | Common Stock | |
| Dr. Alpna Seth, PhD | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 23 Aug 2022 | 663 | 6,848 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 23 Aug 2022 | 663 | 3,801 (0%) | 0% | 150.8 | 99,967 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | 15 Aug 2022 | 6,166 | 6,166 | - | - | Stock Options (Right to Buy) | ||
| Ms. Brenda S. Furlow | SVP - General Counsel | 15 Aug 2022 | 1,984 | 1,984 | - | - | Restricted Stock Units | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 15 Aug 2022 | 300,000 | 300,000 | - | - | Stock Options (Right to Buy) | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 15 Aug 2022 | 13,225 | 13,225 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2022 | 11,305 | 11,305 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | CFO | 15 Aug 2022 | 2,728 | 2,728 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | CFO | 15 Aug 2022 | 8,479 | 8,479 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | PRES. DIAGNOSTICS & GENOM | 15 Aug 2022 | 7,235 | 7,235 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | PRES. DIAGNOSTICS & GENOM | 15 Aug 2022 | 5,426 | 5,426 | - | - | Stock Options (Right to Buy) | ||
| Mr. Kim Kelderman | PRES. DIAGNOSTICS & GENOM | 15 Aug 2022 | 1,746 | 1,746 | - | - | Restricted Stock Units | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2022 | 7,400 | 7,400 | - | - | Stock Options (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2022 | 5,550 | 5,550 | - | - | Stock Options (Right to Buy) | ||
| Mr. William Geist | PRESIDENT, PROTEIN SCIENCES | 15 Aug 2022 | 1,785 | 1,785 | - | - | Restricted Stock Units | ||
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 385.47 per share. | 10 Aug 2022 | 504 | 5,510 (0%) | 0% | 385.5 | 194,277 | Common Stock |
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 380.75 per share. | 10 Aug 2022 | 8 | 5,502 (0%) | 0% | 380.8 | 3,046 | Common Stock |
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 10 Aug 2022 | 3,400 | 8,006 (0%) | 0% | 66.9 | 227,460 | Common Stock |
| Mr. John L. Higgins | Director | 10 Aug 2022 | 3,400 | 0 | - | - | Stock Option (right to buy) | ||
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 373.99 per share. | 10 Aug 2022 | 900 | 7,106 (0%) | 0% | 374.0 | 336,593 | Common Stock |
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 374.90 per share. | 10 Aug 2022 | 100 | 7,006 (0%) | 0% | 374.9 | 37,490 | Common Stock |
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 380.15 per share. | 10 Aug 2022 | 992 | 6,014 (0%) | 0% | 380.2 | 377,112 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 177.32 per share. | 08 Aug 2022 | 563 | 6,523 (0%) | 0% | 177.3 | 99,831 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | 08 Aug 2022 | 563 | 16,562 | - | - | Stock Options (Right to Buy) | ||
| Ms. Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 6,290 (0%) | 0% | 0 | Common Stock | |
| Ms. Brenda S. Furlow | SVP - General Counsel | 07 Aug 2022 | 1,969 | 0 | - | - | Restricted Stock Units | ||
| Ms. Brenda S. Furlow | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 969 | 5,960 (0%) | 0% | 383.0 | 371,098 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 1,969 | 6,929 (0%) | 0% | 0 | Common Stock | |
| Ms. Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 1,330 (0%) | 0% | 0 | Common Stock | |
| Ms. Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 4,960 (0%) | 0% | 0 | Common Stock | |
| Ms. Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 1,330 (0%) | 0% | 0 | Common Stock | |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 16,918 | 251,960 (0%) | 0% | 0 | Common Stock | |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 11,557 | 240,403 (0%) | 0% | 383.0 | 4,425,984 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 07 Aug 2022 | 16,937 | 0 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | Chief Financial Officer | 07 Aug 2022 | 3,938 | 0 | - | - | Restricted Stock Units | ||
| Mr. James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 1,938 | 12,755 (0%) | 0% | 383.0 | 742,196 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 3,938 | 14,693 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 07 Aug 2022 | 2,363 | 0 | - | - | Restricted Stock Units | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 2,363 | 4,352 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 1,214 | 3,138 (0%) | 0% | 383.0 | 464,926 | Common Stock |
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | 28 Jul 2022 | 45,346 | 0 | - | - | Stock Option (right to buy) | ||
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 28 Jul 2022 | 45,346 | 262,749 (0%) | 0% | 108.5 | 4,919,588 | Common Stock |
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 380.76 per share. | 28 Jul 2022 | 27,707 | 235,042 (0%) | 0% | 380.8 | 10,549,717 | Common Stock |
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | 06 Jul 2022 | 50,000 | 45,346 | - | - | Stock Option (right to buy) | ||
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 362.78 per share. | 06 Jul 2022 | 30,935 | 217,403 (0%) | 0% | 362.8 | 11,222,599 | Common Stock |
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 06 Jul 2022 | 50,000 | 248,338 (0%) | 0% | 108.5 | 5,424,500 | Common Stock |
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 364.31 per share. | 07 Jun 2022 | 1,000 | 4,606 (0%) | 0% | 364.3 | 364,310 | Common Stock |
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 07 Jun 2022 | 1,000 | 5,606 (0%) | 0% | 66.9 | 66,900 | Common Stock |
| Mr. John L. Higgins | Director | 07 Jun 2022 | 600 | 3,400 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | 07 Jun 2022 | 1,000 | 4,000 | - | - | Stock Options (Right to Buy) | ||
| Mr. John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 366.09 per share. | 07 Jun 2022 | 600 | 4,606 (0%) | 0% | 366.1 | 219,654 | Common Stock |
| Mr. John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 07 Jun 2022 | 600 | 5,206 (0%) | 0% | 66.9 | 40,140 | Common Stock |
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | 07 Jun 2022 | 5,104 | 95,346 | - | - | Stock Option (right to buy) | ||
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 365.00 per share. | 07 Jun 2022 | 5,104 | 198,338 (0%) | 0% | 365 | 1,862,960 | Common Stock |
| Mr. Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 07 Jun 2022 | 5,104 | 203,442 (0%) | 0% | 108.5 | 553,733 | Common Stock |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Purchase of securities on an exchange or from another person at price $ 352.55 per share. | 10 May 2022 | 300 | 10,106 (0%) | 0% | 352.6 | 105,765 | Common Stock |
| Mr. Robert V. Baumgartner, C.P.A. | Director | Purchase of securities on an exchange or from another person at price $ 352.55 per share. | 10 May 2022 | 300 | 10,106 (0%) | 0% | 352.6 | 105,765 | - |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 08 Feb 2022 | 1,989 | 1,989 (0%) | 0% | 150.8 | 299,901 | - |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 08 Feb 2022 | 1,989 | 7,511 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 08 Feb 2022 | 1,989 | 1,989 (0%) | 0% | 150.8 | 299,901 | Common Stock |
| Mr. William Geist | President, Protein Sciences | 01 Feb 2022 | 2,490 | 2,490 | - | - | Restricted Stock Units | ||
| Mr. William Geist | President, Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 2,490 | 2,490 (0%) | 0% | 0 | - | |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 28 Jan 2022 | 938 | 197,539 (0%) | 0% | 106.6 | 99,981 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 28 Jan 2022 | 799 | 198,338 (0%) | 0% | 125.1 | 99,915 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 28 Jan 2022 | 938 | 256,010 | - | - | Stock Options (Right to Buy) | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 28 Jan 2022 | 799 | 194,771 | - | - | Stock Options (Right to Buy) | ||
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 28 Jan 2022 | 938 | 197,539 (0%) | 0% | 106.6 | 99,981 | - |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 28 Jan 2022 | 799 | 198,338 (0%) | 0% | 125.1 | 99,915 | - |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 503.76 per share. | 19 Nov 2021 | 100 | 400 (0%) | 0% | 503.8 | 50,376 | Common Stock |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 505.78 per share. | 19 Nov 2021 | 400 | 0 (0%) | 0% | 505.8 | 202,313 | Common Stock |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | 19 Nov 2021 | 500 | 2,152 | - | - | Stock Option (Right to Buy) | ||
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 19 Nov 2021 | 500 | 500 (0%) | 0% | 150.8 | 75,390 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 505.49 per share. | 12 Nov 2021 | 2,535 | 1,719 (0%) | 0% | 505.5 | 1,281,407 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.39 per share. | 12 Nov 2021 | 8,989 | 4,254 (0%) | 0% | 504.4 | 4,533,985 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 503.61 per share. | 12 Nov 2021 | 9,043 | 13,243 (0%) | 0% | 503.6 | 4,554,137 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 502.77 per share. | 12 Nov 2021 | 4,054 | 22,286 (0%) | 0% | 502.8 | 2,038,221 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 505.00 per share. | 12 Nov 2021 | 400 | 26,340 (0%) | 0% | 505.0 | 202,002 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.14 per share. | 12 Nov 2021 | 537 | 26,740 (0%) | 0% | 504.1 | 270,725 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 502.99 per share. | 12 Nov 2021 | 300 | 27,277 (0%) | 0% | 503.0 | 150,897 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.78 per share. | 12 Nov 2021 | 200 | 27,577 (0%) | 0% | 504.8 | 100,956 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 12 Nov 2021 | 27,159 | 28,477 (0%) | 0% | 125.1 | 3,396,233 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.09 per share. | 12 Nov 2021 | 700 | 27,777 (0%) | 0% | 504.1 | 352,860 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | 12 Nov 2021 | 799 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. N. David Eansor | President-Protein Sciences | 12 Nov 2021 | 27,159 | 799 | - | - | Stock Options (Right to Buy) | ||
| Mr. N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 12 Nov 2021 | 799 | 2,117 (0%) | 0% | 125.1 | 99,915 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 506.24 per share. | 12 Nov 2021 | 401 | 1,318 (0%) | 0% | 506.2 | 203,002 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | 01 Nov 2021 | 200 | 47,389 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | Chief Financial Officer | 01 Nov 2021 | 8,822 | 47,589 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.10 per share. | 01 Nov 2021 | 200 | 10,755 (0%) | 0% | 525.1 | 105,020 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 200 | 10,955 (0%) | 0% | 125.1 | 25,010 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 528.55 per share. | 01 Nov 2021 | 943 | 10,755 (0%) | 0% | 528.6 | 498,427 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 527.50 per share. | 01 Nov 2021 | 1,433 | 11,698 (0%) | 0% | 527.5 | 755,903 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 526.50 per share. | 01 Nov 2021 | 2,880 | 13,131 (0%) | 0% | 526.5 | 1,516,321 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.61 per share. | 01 Nov 2021 | 3,566 | 16,011 (0%) | 0% | 525.6 | 1,874,318 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 8,822 | 19,577 (0%) | 0% | 125.0 | 1,103,191 | Common Stock |
| Mr. John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 4,606 (0%) | 0% | 0 | Common Stock | |
| Mr. John L. Higgins | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Dr. Joseph D. Keegan, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 2,333 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph D. Keegan, PhD | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Dr. Randolph C. Steer,M.D.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 5,306 (0%) | 0% | 0 | Common Stock | |
| Dr. Randolph C. Steer,M.D.,PhD | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Mr. Robert V. Baumgartner, C.P.A. | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Options (right to buy) | ||
| Mr. Robert V. Baumgartner, C.P.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 9,806 (0%) | 0% | 0 | Common Stock | |
| Dr. Roeland Nusse,PhD | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Dr. Roeland Nusse,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 6,959 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie L. Bushman | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Ms. Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 674 (0%) | 0% | 0 | Common Stock | |
| Mr. James T. Hippel | Chief Financial Officer | 28 Oct 2021 | 662 | 56,411 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.23 per share. | 28 Oct 2021 | 662 | 10,755 (0%) | 0% | 525.2 | 347,704 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 28 Oct 2021 | 662 | 11,417 (0%) | 0% | 125.0 | 82,783 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.18 per share. | 28 Oct 2021 | 100 | 10,755 (0%) | 0% | 525.2 | 52,518 | Common Stock |
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 1,227 (0%) | 0% | 0 | Common Stock | |
| Dr. Alpna Seth, PhD | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Dr. Alpna Seth, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 2,333 (0%) | 0% | 0 | Common Stock | |
| Mr. Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 529.04 per share. | 22 Sep 2021 | 822 | 0 (0%) | 0% | 529.0 | 434,871 | Common Stock |
| Dr. Randolph C. Steer,M.D.,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.39 per share. | 07 Sep 2021 | 4,000 | 9,112 (0%) | 0% | 87.4 | 349,560 | Common Stock |
| Dr. Randolph C. Steer,M.D.,PhD | Director | 07 Sep 2021 | 4,000 | 0 | - | - | Stock Option (right to buy) | ||
| Dr. Randolph C. Steer,M.D.,PhD | Director | 07 Sep 2021 | 4,000 | 0 | - | - | Stock Option (right to buy) | ||
| Dr. Randolph C. Steer,M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 511.45 per share. | 07 Sep 2021 | 500 | 5,112 (0%) | 0% | 511.5 | 255,725 | Common Stock |
| Dr. Randolph C. Steer,M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 510.23 per share. | 07 Sep 2021 | 4,600 | 5,612 (0%) | 0% | 510.2 | 2,347,052 | Common Stock |
| Dr. Randolph C. Steer,M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 509.33 per share. | 07 Sep 2021 | 2,900 | 10,212 (0%) | 0% | 509.3 | 1,477,046 | Common Stock |
| Dr. Randolph C. Steer,M.D.,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.78 per share. | 07 Sep 2021 | 4,000 | 13,112 (0%) | 0% | 91.8 | 367,120 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 509.67 per share. | 02 Sep 2021 | 5,295 | 9,196 (0%) | 0% | 509.7 | 2,698,711 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 510.82 per share. | 02 Sep 2021 | 1,576 | 7,620 (0%) | 0% | 510.8 | 805,054 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | 02 Sep 2021 | 6,871 | 9,503 | - | - | Stock Options (Right to Buy) | ||
| Ms. Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 02 Sep 2021 | 6,871 | 14,491 (0%) | 0% | 125.1 | 859,219 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 510.78 per share. | 02 Sep 2021 | 42,005 | 196,601 (0%) | 0% | 510.8 | 21,455,314 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 02 Sep 2021 | 73,492 | 238,606 (0%) | 0% | 108.5 | 7,973,147 | Common Stock |
| Mr. Charles R. Kummeth | Director, Chief Executive Officer | 02 Sep 2021 | 73,492 | 100,450 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | Chief Financial Officer | 02 Sep 2021 | 10,000 | 0 | - | - | Stock Options (Right to Buy) | ||
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 509.14 per share. | 02 Sep 2021 | 7 | 10,855 (0%) | 0% | 509.1 | 3,564 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 507.22 per share. | 02 Sep 2021 | 9,993 | 10,862 (0%) | 0% | 507.2 | 5,068,600 | Common Stock |
| Mr. James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 02 Sep 2021 | 10,000 | 20,855 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Mr. N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 503.07 per share. | 31 Aug 2021 | 1,538 | 1,318 (0%) | 0% | 503.1 | 773,728 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 506.12 per share. | 31 Aug 2021 | 3,108 | 7,620 (0%) | 0% | 506.1 | 1,573,011 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 505.26 per share. | 31 Aug 2021 | 1,569 | 10,728 (0%) | 0% | 505.3 | 792,755 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 503.24 per share. | 31 Aug 2021 | 323 | 12,297 (0%) | 0% | 503.2 | 162,546 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 31 Aug 2021 | 5,000 | 12,620 (0%) | 0% | 125.1 | 625,250 | Common Stock |
| Ms. Brenda S. Furlow | SVP - General Counsel | 31 Aug 2021 | 5,000 | 16,374 | - | - | Stock Options (Right to Buy) | ||
| Mr. Robert V. Baumgartner, C.P.A. | Director | Sale of securities on an exchange or to another person at price $ 481.77 per share. | 23 Aug 2021 | 299 | 13,313 (0%) | 0% | 481.8 | 144,050 | Common Stock |
| Mr. Robert V. Baumgartner, C.P.A. | Director | 23 Aug 2021 | 4,000 | 0 | - | - | Stock Options (right to buy) |